Screening and Treating Adults for Lipid Disorders: Summary of the Evidence. Screening and Treating Adults for Lipid Disorders: Summary of the Evidence, Table 3

You Are Here: AHRQ Home > Clinical Information > U.S. Preventive Services Task Force (USPSTF) > New Recommendations Issued for Preventive Services > Screening and Treating Adults for Lipid Disorders: Summary of the Evidence

Table 3. Primary Prevention Trials of Drug Therapy: Results*

Study details	LRC (34)	Helsinki (35)	WOSCOPS (36)	AFCAPS(37)
Year	1984	1987	1995	1998
Main outcome	Nonfatal MI, CHD death	Nonfatal MI, CHD death	Nonfatal MI, CHD death	Nonfatal MI, CHD death, unstable angina
Cumulative event rate^a	8.1/9.8	2.73/4.14	5.5/7.9	3.4/5.45
I/C	(5.5/6.6)^b			1.65/2.9^c
ARR	1.7 (1.1)^b	1.41	2.4	2.05 (1.25)^c
NNT for 5 years^e	(91)^b	71	42	49 (80)^c
RRR (%)	19	34	31	37
(95% CI)	(3-32)^d	(8-53)	(17-43)	(21-50)

^[a] Event rates are cumulative incidence in percentages for the event over the study; I, intervention, C, control.
^[b] Adjusted 5-year outcomes for LRC.
^[c] Unstable angina excluded in results.
^[d] CI for LRC was 90%.
^[e] NNT for 5 years to prevent 1 CHD event.

*LRC, Lipids Research Council; HHS, Helsinki Heart Study; WOSCOPS, West of Scotland Coronary Prevention Study; AFCAPS, Air Force/Texas Coronary Atherosclerosis Prevention; MI, myocardial infarction; CHD, coronary heart disease; ARR, absolute risk reduction; NNT, numbers needed to treat; RRR, relative risk reduction; CI, confidence interval.

Return to Document